Cloning and Expression of Truncated Protein of Epidermal Growth Factor-1 (EGFR-1) in Pichia Pastoris Yeast Host

Document Type : Original Article (s)

Authors

1 Associate Professor, Biotechnology Research Center, Yazd International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 MSc Student, Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 PhD Candidate, Department of Genetics, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran

4 MSc Student, Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

5 Assistant Professor, Department of Immunology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

6 Professor, Biotechnology Research Center, Yazd International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

7 Assistant Professor, Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Epidermal growth factor receptor (EGFR) plays a major role in the pathophysiology of a wide variety of solid tumors such as glioblastoma and breast cancer. Therefore, blocking of signaling cascade of this receptor via specific antibodies is an appropriate therapeutic target against these cancers. The first step to make monoclonal antibodies is production of recombinant protein with high purity and glycosylation pattern similar to human protein. One of the best available hosts for this purpose is the Pichia pastoris yeast.Methods: Coding sequence of extracellular and transmembrane domain of EGFR protein was isolated from human glioma cell line (A172) using real-time polymerase chain reaction (RT-PCR) technique. This sequence was cloned into plasmid pPicZαA and transferred into Pichia pastoris yeast cells. Then, the production of recombinant protein was induced via treating of cells with methanol with final concentration of 0.5%, in several time periods, 24, 48, 72, 96, 120, 144, 168 and 192 hours. Protein production was assessed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).Findings: Partial coding sequence of EGFR was cloned in pICZαA plasmid. The results of induction of protein expression on SDS-PAGE gel showed that the protein expression increased as incubation time increased. However, after three days of induction, the secreted host proteins in the culture medium increased and got visible on SDS-PAGE gel.Conclusion: In this study, we produced EGFR protein that can dramatically speed up production process of EGFR inhibiting monoclonal antibodies.

Keywords

References

  1. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19(2): 124-34.
  2. Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev 2014; 40(4): 567-77.
  3. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci 2005; 1056: 206-17.
  4. Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002; 297(5585): 1330-3.
  5. Liffers K, Lamszus K, Schulte A. EGFR Amplification and Glioblastoma Stem-Like Cells. Stem Cells Int 2015; 2015: 427518.
  6. Chen W, Zhong X, Wei Y, Liu Y, Yi Q, Zhang G, et al. TGF-beta Regulates Survivin to Affect Cell Cycle and the Expression of EGFR and MMP9 in Glioblastoma. Mol Neurobiol 2015.
  7. Becher OJ, Peterson KM, Khatua S, Santi MR, MacDonald TJ. IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. J Child Neurol 2008; 23(10): 1205-13.
  8. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24(16): 1731-45.
  9. Velpula KK, Dasari VR, Asuthkar S, Gorantla B, Tsung AJ. EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells. Transl Oncol 2012; 5(5): 379-92.
  10. Zahonero C, Sanchez-Gomez P. EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. Cell Mol Life Sci 2014; 71(18): 3465-88.
  11. Schulte A, Liffers K, Kathagen A, Riethdorf S, Zapf S, Merlo A, et al. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110delta. Neuro Oncol 2013; 15(10): 1289-301.
  12. Carrasco-Garcia E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, Gomez-Martinez A, et al. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res 2011; 317(10): 1476-89.
  13. Wang Y, Pan L, Sheng XF, Chen S, Dai JZ. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Asia Pac J Clin Oncol 2014.
  14. Gong B, Cukan M, Fisher R, Li H, Stadheim TA, Gerngross T. Characterization of N-linked glycosylation on recombinant glycoproteins produced in Pichia pastoris using ESI-MS and MALDI-TOF. Methods Mol Biol 2009; 534: 213-23.
  15. Sangar V, Funk CC, Kusebauch U, Campbell DS, Moritz RL, Price ND. Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells. Mol Cell Proteomics 2014; 13(10): 2618-31.
  16. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007; 6(3): 1167-74.
  17. Kapoor GS, Christie A, O'Rourke DM. EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53. Cancer Biol Ther 2007; 6(4): 571-9.
  18. Wu CJ, Chen Z, Ullrich A, Greene MI, O'Rourke DM. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs). Oncogene 2000; 19(35): 3999-4010.
  19. Chung D, Young J, Bomble YJ, Vander Wall TA, Groom J, Himmel ME, et al. Homologous expression of the Caldicellulosiruptor bescii CelA reveals that the extracellular protein is glycosylated. PLoS One 2015; 10(3): e0119508.
  20. Miele RG, Nilsen SL, Brito T, Bretthauer RK, Castellino FJ. Glycosylation properties of the Pichia pastoris-expressed recombinant kringle 2 domain of tissue-type plasminogen activator. Biotechnol Appl Biochem 1997; 25 ( Pt 2): 151-7.
Journal of Isfahan Medical School
Volume 33, Issue 364 - Serial Number 364
November and December 2016
Pages 2232-2238

Files

History

  • Receive Date: 09 July 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics